Drugs / COV155
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02767349 | Jan 2016 → Apr 2017 | — | Mallinckrodt | Withdrawn | No outcome recorded |
| Phase 1 | NCT02561650 | Dec 2011 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01743625 | Nov 2012 → May 2013 | neuropathy, painful, toe, misshapen | Mallinckrodt | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02381132 Comparator | Nov 2014 → Dec 2015 | — | Neil Singla | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COV155 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02561650 ↗ |
| Known as | MNK 155 | “The main study drug of interest in this study is MNK 155.” NCT02381132 ↗ |
| Route | Oral | “oral MNK155 and Norco® 7.5mg/325mg” NCT02381132 ↗ |